secwatch.observer — SEC 8-K summary
======================================

Issuer:     Wave Life Sciences Ltd. (WVE)
CIK:        0001631574
Form:       8-K
Filed at:   2026-02-02T23:59:59+00:00
Accession:  0001193125-26-032698
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Wave regains full rights to WVE-006; plans FDA accelerated approval engagement mid-2026
--------------------------------------------------------------------------------

- Regained full rights to WVE-006 (RNA editing for AATD) from GSK; no upfront payment mentioned.
- Plans to engage FDA on accelerated approval pathway; regulatory feedback expected mid-2026.
- 400 mg multidose cohort data from RestorAATion-2 on track for Q1 2026; 600 mg data expected in 2026.
- GSK collaboration continues; fourth program selected in Jan 2026; potential milestones up to $2.8B.
- Cash runway expected into Q3 2028; milestone payments from GSK not included in runway.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1631574/000119312526032698/0001193125-26-032698-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1631574/000119312526032698/d78838d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-032698

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer